With a big stake in hand, Saman­tha Du files for $115M IPO for Zai Lab

In three years Shang­hai-based Zai Lab has in-li­censed a pipeline of 6 clin­i­cal-stage ther­a­peu­tics from a group of small and large glob­al play­ers, moved to the start of its first Phase III tri­al and built out its first man­u­fac­tur­ing fa­cil­i­ty — with a big­ger op­er­a­tion on the draw­ing board.

Now the ex­ecs at Zai Lab want to raise around $115 mil­lion in a US IPO to keep the gas ped­al pressed to the floor as the biotech, led by Saman­tha Du, con­tin­ues to charge ahead on three key dis­ease fronts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER